Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
March 13 2024 - 7:30AM
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)
(“Clearmind” or the "company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, today announced that
it has applied and received approval for a voluntary delisting of
its common shares from the Canadian Securities Exchange ("CSE").
The delisting from the CSE will not affect the company's listing on
the NASDAQ Capital Market (the "NASDAQ"). The common shares will
continue to trade on the NASDAQ under the symbol CMND.
The company believes that the trading volume of its shares on
the CSE no longer justifies the expenses and administrative efforts
required to maintain a dual listing. The company also believes that
delisting from the CSE will create a central marketplace for its
common shares on the NASDAQ, and ultimately benefit the long-term
liquidity and shareholder value of the company.
It is anticipated that, effective as at the close of trading on
March 14, 2024, Clearmind’s common shares will no longer be listed
and posted for trading on the CSE.
Following delisting from the CSE, Clearmind’s shareholders can
trade their common shares through their brokers on NASDAQ. As most
brokers in Canada, including many discount and online brokers, have
the ability to buy and sell securities listed on NASDAQ,
Clearmind’s NASDAQ listing will continue to provide shareholders
with the same accessibility to trade the company's common shares.
Shareholders holding shares in Canadian brokerage accounts should
contact their brokers to confirm how to trade Clearmind’s shares on
the NASDAQ.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
fifteen patent families. The Company intends to seek additional
patents for its compounds whenever warranted and will remain
opportunistic regarding the acquisition of additional intellectual
property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the
Canadian Securities Exchange under the symbol "CMND" and the
Frankfurt Stock Exchange under the symbol “CWY.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relationsinvest@clearmindmedicine.comTelephone: (604)
260-1566US: CMND@crescendo-ir.com
General
InquiriesInfo@Clearmindmedicine.comwww.Clearmindmedicine.com
Forward-Looking
Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses how its delisting from
the CSE will create a central marketplace for its common shares on
the NASDAQ, and ultimately benefit the long-term liquidity and
shareholder value of the company. Forward-looking statements are
not historical facts, and are based upon management’s current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual performance or results to
differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and
uncertainties affecting the Company, reference is made to the
Company’s reports filed from time to time with the Securities and
Exchange Commission (“SEC”), including, but not limited to, the
risks detailed in the Company’s annual report on Form 20-F filed
with the SEC on January 29, 2024. Forward-looking statements speak
only as of the date the statements are made. The Company assumes no
obligation to update forward-looking statements to reflect actual
results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information
except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no
inference should be drawn that the Company will make additional
updates with respect thereto or with respect to other
forward-looking statements. References and links to websites have
been provided as a convenience, and the information contained on
such websites is not incorporated by reference into this press
release. Clearmind is not responsible for the contents of
third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Jul 2024 to Aug 2024
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Aug 2023 to Aug 2024